Exclusive news, analysis, and commentary on Big Pharma, hospitals, and biotech.
It’s just another earnings week in the life of pharmaceutical CEOs, with blockbuster expectations running up against cruel reality.
Modifi Biosciences announced that it has been acquired by global pharmaceutical giant Merck, with a $30 million down payment.
Walmart announced on Tuesday that it’s introducing a new same-day delivery service for prescription medication.
A new study suggests increasingly popular GLP-1 drugs could help cut opioid and alcohol abuse nearly in half.
Bausch + Lomb has stirred up significant interest from the pair of private equity giants, TPG and Blackstone.
New estimates say that Medicare will spend tens of billions of dollars over nine years to cover weight-loss drugs.
Gritstone Bio announced it is “taking action” to “preserve value and strengthen capital structure” on Thursday.
UnitedHealth, CVS, and Cigna want FTC chair Lina Khan and two other officials recused from their case due to alleged biases.
Obesity drugmaker Rivus is working with banks to complete a US public listing that could happen before the end of the year.
Amazon’s patent to help doctors take better notes highlights the company’s massive bet on the healthcare space.
The Food and Drug Administration declared an end to the scarcity of Eli Lilly’s highly in-demand weight-loss and diabetes drugs on Thursday.
Dallas-based Steward Health Care is may just well be the poster child for private equity investment in healthcare gone wrong.
The insurance industry needs to be careful when using AI, or else AI black boxes could render consumers uninsurable without any explanation.
In the obesity drug industry, two players have really been throwing their weight around. There isn’t a third in sight.
Moderna walked a tightrope trying to convince shareholders it can both develop a new portfolio of drugs and keep costs down in the process.
AI has a lot of promise in the healthcare industry in areas such as documentation, imaging, and quicker diagnostics as staffing shortages loom.
Data from two promising vaccine trials heralded potential breakthroughs in the treatment of pneumococcal infection and Lyme disease.
The World Health Organization has declared mpox to be a public health emergency, and pharmaceutical and healthcare winners have emerged.
Novo Nordisk’s share price fell over 8% on Wednesday after the company reported lower-than-expected sales of Wegovy.
WW announced on Thursday that it will be laying off employees and cutting costs to the tune of $100 million per year.